Outpace Bio
Outpace Bio develops AI-powered protein design technologies to create engineered cell therapies for cancer treatment. Its platform programs cells to improve potency, specificity, persistence, and safety, aiming to make cell therapies effective, safe, and scalable across diverse cancer indications. The organization’s mission is to cure cancer by overcoming biological barriers through advanced cellular engineering.
Facts
- HQ
- Seattle, Washington, US
- Sectors
- Biotechnology Research
- Founded
- 2020
- Type
- Corporation Seattle business license
- Employees
- 74
- Registered name
- Outpace Bio Inc Seattle business license
- Stage
- Series A
- Members see funding amounts. .
Is this your organization? Claim it
Outpace Bio halts Phase 1 mesothelin CAR‑T ovarian cancer trial; Incyte showcases impressive ESMO data
Outpace Bio halted a Phase 1 ovarian cancer mesothelin CAR‑T trial, while Incyte reported strong data at ESMO; the briefing also notes cuts at Genmab and updates on Rumi, Prana, and Fractyl.
Fred Hutch-Led Synthesize Bio Raises $10M to Accelerate Drug Discovery Using AI Gene Expression Model
Seattle-based Synthesize Bio, led by Fred Hutchinson Cancer Center researchers, raised $10 million from Madrona to accelerate drug discovery using their AI model GEM-1, which predicts gene expression outcomes with lab-level accuracy. The startup aims to reduce drug development time and costs by simulating hypothetical lab experiments with generative genomics.
Seattle Biotech Tune Therapeutics Raises $175M to Advance Epigenetic Editing Trials for Chronic Hepatitis B
Seattle-based biotech startup Tune Therapeutics raised $175 million to support clinical trials of its epigenetic editing treatments for chronic Hepatitis B. The funding will aid development of therapies that control gene expression without altering DNA, leveraging technology developed at Duke University.
See all 7 stories, episodes and videos about Outpace Bio.
Seattle Flow is free for everyone.
- Claim and edit your profile
- Get alerts about you, your company, and anything else you care about
- Access the most comprehensive investor list in Seattle
- Join the conversation on news, podcasts, and events
People
See all 5-
Marc Lajoie Executive Officer, Director, Promoter, Co-founder & Chief Executive Officer
-
Scott Boyken Executive Officer, Director, Promoter, Co-founder & Chief Innovation Officer
-
Aaron Foster Executive, Executive Officer, Chief Scientific Officer